Malignant pleural mesothelioma: current treatments and emerging drugs
- 24 June 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Emerging Drugs
- Vol. 14 (3) , 423-437
Abstract
(2009). Malignant pleural mesothelioma: current treatments and emerging drugs. Expert Opinion on Emerging Drugs: Vol. 14, No. 3, pp. 423-437. doi: 10.1517/14728210903074563Keywords
This publication has 87 references indexed in Scilit:
- Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trialsBritish Journal of Cancer, 2008
- Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesotheliomaBritish Journal of Cancer, 2008
- Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810)Lung Cancer, 2008
- Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexedThorax, 2007
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamstersProceedings of the National Academy of Sciences, 2006
- TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesisProceedings of the National Academy of Sciences, 2006
- The activity of raltitrexed (Tomudex®) in malignant pleural mesotheliomaEuropean Journal of Cancer, 2003
- The language of covalent histone modificationsNature, 2000
- Differential expression of platelet derived growth factor-β in malignant mesothelioma: a clue to future therapies?Surgical Oncology, 1993